financetom
Business
financetom
/
Business
/
Edgewell Personal Care Q4 sales slightly beat estimates, to sell Feminine Care business for $340 mln
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Edgewell Personal Care Q4 sales slightly beat estimates, to sell Feminine Care business for $340 mln
Nov 13, 2025 3:35 AM

Overview

* Edgewell Q4 net sales rose 3.8%, slightly beating analyst expectations

* Adjusted EPS for Q4 missed analyst expectations

* On Nov 13, company announced $100 mln share repurchase authorization

* Edgewell to sell Feminine Care business to Essity for $340 mln

Outlook

* Edgewell expects 2026 reported net sales to increase 0.5% to 3.5%

* Company projects 2026 GAAP EPS between $1.10 and $1.50

* Adjusted EPS for 2026 expected to be $2.15 to $2.55

Result Drivers

* INTERNATIONAL GROWTH - Co reports 6.9% organic sales growth in international markets, driven by volume and price gains

* PROMOTIONAL IMPACT - Increased promotional levels in North America offset volume gains, leading to a 0.6% organic sales decline

* DIVESTITURE STRATEGY - Sale of Feminine Care business to Essity for $340 mln marks strategic shift to focus on core personal care segments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Sales Slight $537.20 $534.30

Beat* mln mln (6

Analysts

)

Q4 Miss $0.68 $0.80 (8

Adjusted Analysts

EPS )

Q4 Miss $40.30 $50.20

Adjusted mln mln (6

Operatin Analysts

g Income )

Q4 Gross $208.60

Profit mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the personal products peer group is "hold."

* Wall Street's median 12-month price target for Edgewell Personal Care Co ( EPC ) is $25.50, about 25.8% above its November 12 closing price of $18.91

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved